• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用腺苷调节剂阿卡地辛激活机体自身的心脏防御机制:内皮的重要性

Harnessing nature's own cardiac defense mechanism with acadesine, an adenosine regulating agent: importance of the endothelium.

作者信息

Engler R L

机构信息

Research Service, Veterans Affairs Medical Center, San Diego, CA 92161.

出版信息

J Card Surg. 1994 May;9(3 Suppl):482-92. doi: 10.1111/jocs.1994.9.3s.482.

DOI:10.1111/jocs.1994.9.3s.482
PMID:8069041
Abstract

Although the effects of adenosine on the heart, including the clinical suppression of cardiac arrhythmias, have been recognized for more than half a century, it is only in the last decade that the therapeutic potential of adenosine has been recognized. Research related to the clinical application of adenosine has concentrated on two areas. The first came directly from early observations about the use of adenosine in treating cardiac arrhythmias, in particular supraventricular tachycardias. The second relates to the use of adenosine to protect the heart from the deleterious consequences of myocardial ischemia and reperfusion. This review will focus on the latter cardioprotective properties of adenosine, particularly those shown by a novel group of drugs termed adenosine regulating agents, the prototype of which is acadesine (Protara).

摘要

尽管半个多世纪以来人们已经认识到腺苷对心脏的作用,包括在临床上对心律失常的抑制作用,但直到最近十年,腺苷的治疗潜力才得到认可。与腺苷临床应用相关的研究集中在两个领域。第一个领域直接源于早期关于腺苷用于治疗心律失常,特别是室上性心动过速的观察。第二个领域涉及使用腺苷保护心脏免受心肌缺血和再灌注的有害影响。本综述将聚焦于腺苷的后一种心脏保护特性,特别是一类称为腺苷调节剂的新型药物所表现出的特性,其原型是阿卡地辛(普罗塔拉)。

相似文献

1
Harnessing nature's own cardiac defense mechanism with acadesine, an adenosine regulating agent: importance of the endothelium.利用腺苷调节剂阿卡地辛激活机体自身的心脏防御机制:内皮的重要性
J Card Surg. 1994 May;9(3 Suppl):482-92. doi: 10.1111/jocs.1994.9.3s.482.
2
Acadesine: a unique cardioprotective agent for myocardial ischemia.阿卡地辛:一种用于心肌缺血的独特心脏保护剂。
Heart Dis. 1999 Sep-Oct;1(4):255-60.
3
Effects of adenosine and acadesine on interstitial nucleosides and myocardial stunning in the pig.
Can J Physiol Pharmacol. 1999 Apr;77(4):259-67.
4
Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury.
Cardiovasc Res. 1993 Jan;27(1):43-7. doi: 10.1093/cvr/27.1.43.
5
Acadesine improves tolerance to ischemic injury in rat cardiac myocytes.
J Mol Cell Cardiol. 1994 Sep;26(9):1187-95. doi: 10.1006/jmcc.1994.1137.
6
Acadesine: preclinical overview.阿卡地新:临床前概述。
Adv Exp Med Biol. 1994;370:423-6. doi: 10.1007/978-1-4615-2584-4_91.
7
Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat.阿卡地新与心肌保护。大鼠给药时间及剂量反应关系的研究。
Circulation. 1992 Aug;86(2):598-608. doi: 10.1161/01.cir.86.2.598.
8
Acadesine, an adenosine-regulating agent with the potential for widespread indications.阿卡地辛,一种具有广泛适应症潜力的腺苷调节剂。
Expert Opin Pharmacother. 2008 Aug;9(12):2137-44. doi: 10.1517/14656566.9.12.2137.
9
Sustained protection by acadesine against ischemia- and reperfusion-induced injury. Studies in the transplanted rat heart.
Circulation. 1992 Aug;86(2):589-97. doi: 10.1161/01.cir.86.2.589.
10
Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine.再灌注后心肌梗死:使用阿卡地新调节腺苷以改善长期生存率
J Am Coll Cardiol. 2006 Jul 4;48(1):206-14. doi: 10.1016/j.jacc.2006.04.044. Epub 2006 May 11.

引用本文的文献

1
Extracellular guanosine regulates extracellular adenosine levels.细胞外鸟苷调节细胞外腺苷水平。
Am J Physiol Cell Physiol. 2013 Mar 1;304(5):C406-21. doi: 10.1152/ajpcell.00212.2012. Epub 2012 Dec 12.
2
Enhancement of adenosine A1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro.苯甲酰噻吩类化合物在体外增强豚鼠组织中腺苷A1受体功能的研究
Naunyn Schmiedebergs Arch Pharmacol. 1995 Aug;352(2):206-12. doi: 10.1007/BF00176776.